Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease - Report - MDSpire
Advertisement
Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease
Clinical Report: Proteomic and Metabolomic Profiling in Multiple Myeloma
Overview
Revise to better articulate the comparison of MS techniques with traditional MRD monitoring methods.
Background
Multiple myeloma (MM) is a complex malignancy characterized by diverse genetic alterations and variable clinical outcomes. Current prognostic models, such as the Revised International Staging System (R-ISS), are limited by their static nature and inability to account for dynamic disease changes. The integration of mass spectrometry for biomarker discovery and MRD monitoring represents a significant advancement in the management of MM.
Data Highlights
Adjust the table format to match the source and ensure all findings are included.
Key Findings
MS-based biomarkers retained independent prognostic significance in multivariate models adjusted for R-ISS.
Specific microenvironmental proteins and lipid metabolites were consistently associated with patient outcomes.
MS techniques achieved high concordance with bone marrow-based assays.
MRD negativity correlates with improved overall survival and progression-free survival.
Standardization of MS methodologies is essential for clinical implementation.
Clinical Implications
Elaborate on the potential changes in clinical practice due to MS-based profiling.
Conclusion
Quantitative mass spectrometry offers a promising approach to refine prognostic assessments and improve monitoring of minimal residual disease in multiple myeloma, paving the way for more personalized treatment strategies.
